drugset / Trial / NCT01185366
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
RandomizedCrossoverOpen-labelTreatment
Summary
The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer). The safety of each treatment will also be studied.
Timeline
- Start
- 2010-08
- Primary completion
- 2019-09-09
- Completion
- 2019-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Comparator | Sunitinib | Small molecule | 50 mg | Oral |